Option Care Health (NASDAQ:OPCH) Receives "Market Outperform" Rating from JMP Securities

Option Care Health (NASDAQ:OPCH - Get Free Report)'s stock had its "market outperform" rating restated by analysts at JMP Securities in a report issued on Tuesday,Benzinga reports. They currently have a $36.00 price target on the stock. JMP Securities' target price points to a potential upside of 15.20% from the stock's current price.

OPCH has been the topic of a number of other reports. Barrington Research restated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a research note on Monday. Bank of America raised Option Care Health from a "neutral" rating to a "buy" rating and raised their price objective for the company from $26.00 to $33.00 in a research report on Monday, January 13th. Jefferies Financial Group upgraded Option Care Health from a "hold" rating to a "buy" rating and increased their price objective for the company from $26.00 to $35.00 in a report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $33.75.

Option Care Health Trading Down 2.4 %

Shares of Option Care Health stock opened at $31.25 on Tuesday. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 2.30 and a beta of 1.07. Option Care Health has a twelve month low of $21.39 and a twelve month high of $35.53. The business has a 50-day moving average price of $33.32 and a 200-day moving average price of $28.66.

Insider Buying and Selling

In other news, insider Michael Bavaro sold 30,996 shares of the company's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the transaction, the insider now directly owns 44,974 shares of the company's stock, valued at $1,495,835.24. This represents a 40.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.64% of the stock is owned by company insiders.

Institutional Investors Weigh In On Option Care Health

A number of large investors have recently bought and sold shares of the stock. Murphy & Mullick Capital Management Corp purchased a new position in shares of Option Care Health during the fourth quarter valued at approximately $26,000. UMB Bank n.a. boosted its holdings in shares of Option Care Health by 41.7% in the 4th quarter. UMB Bank n.a. now owns 1,176 shares of the company's stock valued at $27,000 after purchasing an additional 346 shares during the last quarter. Signaturefd LLC grew its stake in shares of Option Care Health by 487.9% during the 4th quarter. Signaturefd LLC now owns 1,211 shares of the company's stock valued at $28,000 after buying an additional 1,005 shares during the period. Quadrant Capital Group LLC increased its holdings in shares of Option Care Health by 172.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company's stock worth $40,000 after buying an additional 1,099 shares during the last quarter. Finally, Public Employees Retirement System of Ohio raised its holdings in shares of Option Care Health by 21.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock worth $43,000 after purchasing an additional 332 shares during the period. Institutional investors and hedge funds own 98.05% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.